RxDoctor Payments Data

Golnaz Vahdani, MD

Nephrology · Glendale, AZNPI 1497118889

Payments from drug & device makers

$518in general payments, 2019–2025

Across 20 payments — averaging $25.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$196
  • Medtronic$101
  • Mallinckrodt Hospital Products Inc.$65
  • Daiichi Sankyo Inc.$48
  • Amgen$31
  • Bayer$23
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$518 in reported general payments places this provider in the 20th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$75,909
Medicare patients
254
Services billed
720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol92$100,129
TrulicityDulaglutide22$31,610
LokelmaSodium Zirconium Cyclosilicate28$23,596
JardianceEmpagliflozin14$18,397
Sevelamer Carbonate12$3,466
Nifedipine ErNifedipine50$1,428
Telmisartan42$1,225
Potassium Citrate ErPotassium Citrate13$1,082
Bumetanide37$843
Losartan Potassium45$549
Chlorthalidone24$396
Carvedilol56$380
Calcitriol14$364
Hydralazine Hcl17$262
Amlodipine Besylate38$260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$196$123,725120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 259 nephrology providers in Arizona.

Other nephrology in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →